AstraZeneca Sues Mylan Over Nexium Patents

Law360, New York (March 8, 2012, 12:41 PM EST) -- AstraZeneca AB on Wednesday sued Mylan Laboratories Ltd. in New Jersey federal court for allegedly relying on AstraZeneca patents to make a generic version of Nexium, its latest infringement complaint over the acid reflux drug.

Sweden-based AstraZeneca alleges that Mylan's recently filed abbreviated new drug application with the U.S. Food and Drug Administration for generic Nexium uses drug formulas and methods for treating reflux that are covered by three AstraZeneca patents, according to the suit.

In a Jan. 24 letter to the FDA announcing its intention...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.